阿替普酶与尿酸激酶在急性脑梗死治疗中的疗效及安全性比较

摘要

Objective To compare the curative effect and security of alteplase and uric acid kinase treatment for acute cerebral infarction.Methods 82 cases of patients with acute cerebral infarction from March 2014 to February 2015 in our hospital, according to the draw method, were divided into experimental group and control group, 41 cases in each group.Experimental group patients were taken alteplase for treatment, the control group were treated with uric acid kinase.Before and after treatment, compare two groups patients with nerve function defect score (NIHSS score) and daily life ability score (ADL score).The clinical curative effect and complications of two groups were observed.Results After treatment, the total clinical efficacy rate of the experimental group and control group respectively was 82.93% (34/41), 78.05% (32/41), comparison between groups had no obvious difference (P>0.05).NIHSS scores and ADL scores in experimental group respectively was [(14.52±1.21) points, (73.08±4.08) points], and the control group was [(14.67±1.24) points, (73.72±3.14) points], there had no significant difference (P>0.05).Bleeding complications incidence rate in experimental group was 19.12% (8/41) and the control group 21.95% (9/41), there had no significant difference (P>0.05).Conclusion Patients with acute cerebral infarction application for alteplase and uric acid, can effectively improve the patient's nerve functions, daily life ability.There has no difference between the clinical curative effect, and the security is the same.%目的 比较阿替普酶与尿酸激酶在急性脑梗死治疗中的疗效及安全性.方法 选取2014年3月至2015年2月收治的82例急性脑梗死患者,根据抽签法分为试验组和对照组,各41例.试验组患者采取阿替普酶进行治疗,对照组患者采取尿酸激酶进行治疗.比较两组患者治疗前后神经功能缺损评分(NIHSS评分)和日常生活能力评分(ADL评分),并观察两组患者的临床疗效和并发症情况.结果 治疗后,试验组和对照组总的临床总有效率分别为82.93%(34/41)、78.05%(32/41),组间比较无显著差异(P>0.05).试验组的NIHSS评分和ADL评分分别为[(14.52±1.21)分、(73.08±4.08)分],与对照组[(14.67±1.24)分、(73.72±3.14)分]比较,无显著差异(P>0.05).试验组的出血并发症发生率19.12%(8/41)和对照组21.95%(9/41)比较无显著差异(P>0.05).结论 急性脑梗死患者应用阿替普酶与尿酸激酶,均能有效改善患者的神经功能、日常生活能力,所产生的临床疗效无显著差异,安全性相当.